Beta-lactam comprehensive allergy management program in a community medical center.
Journal
Antimicrobial stewardship & healthcare epidemiology : ASHE
ISSN: 2732-494X
Titre abrégé: Antimicrob Steward Healthc Epidemiol
Pays: England
ID NLM: 9918266096106676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
06
2023
revised:
29
08
2023
accepted:
30
08
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
The Beta-lactam Comprehensive Allergy Management Program (CAMP) was implemented to facilitate complete beta-lactam allergy history documentation in the electronic medical record (EMR) and increase beta-lactam utilization. The study objective was to assess the rate of complete allergy histories and days of antimicrobial therapy (DOT) before versus after CAMP implementation. Quasi-experimental study with interrupted time-series analysis. Non-teaching, urban, and community medical center within a multi-hospital health system. Adult inpatients with a beta-lactam allergy receiving antimicrobial therapy. The multidisciplinary CAMP team screened, interviewed, and collected allergy history details of adult inpatients with a beta-lactam allergy receiving antimicrobial therapy starting January 4, 2021. Patients were stratified as high, moderate, or low risk of IgE-mediated allergy and referred to an allergist for skin testing or drug challenge. The EMR was updated with interview details and drug challenge or skin test results. The primary endpoint was rate of complete allergy history documentation before (12/1/18-4/1/19) compared to after (1/4/21-5/1/21) program implementation. The secondary endpoint was days of inpatient beta-lactam therapy. Implementation logistics, de-labeling rate, and antimicrobial therapy changes were evaluated. The program evaluated 392 individuals, with 184 and 208 patients comprising the pre- and post-intervention groups, respectively. The post-intervention period was associated with an increase of 19.8% in complete allergy histories (0.359 PPc; Implementation of a comprehensive beta-lactam allergy management program was associated with higher rates of complete beta-lactam allergy history and beta-lactam use.
Identifiants
pubmed: 38028889
doi: 10.1017/ash.2023.461
pii: S2732494X23004618
pmc: PMC10654959
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e189Informations de copyright
© The Author(s) 2023.
Déclaration de conflit d'intérêts
Dr. Donald Beggs is a physician speaker for AbbVie Inc. The remaining authors report no conflicts of interest relevant to this article.
Références
Pharmacotherapy. 2013 Aug;33(8):856-67
pubmed: 23712569
Ann Allergy Asthma Immunol. 2011 Jan;106(1):1-7
pubmed: 21195938
Ann Pharmacother. 2020 Apr;54(4):364-370
pubmed: 31701755
Clin Infect Dis. 2016 May 15;62(10):e51-77
pubmed: 27080992
Ann Allergy Asthma Immunol. 2010 Oct;105(4):259-273
pubmed: 20934625
J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1349-1355
pubmed: 29242142
Clin Infect Dis. 2016 Oct 1;63(7):904-910
pubmed: 27402820
Arch Fam Med. 2000 Aug;9(8):722-6
pubmed: 10927711
J Allergy Clin Immunol. 2014 Mar;133(3):790-6
pubmed: 24188976
J Allergy Clin Immunol Pract. 2019 Sep - Oct;7(7):2105-2114
pubmed: 31495420
Ann Intern Med. 2007 Feb 20;146(4):266-9
pubmed: 17310050
Fam Pract. 2015 Jun;32(3):257-62
pubmed: 25851993
J Allergy Clin Immunol Pract. 2013 May-Jun;1(3):258-63
pubmed: 24565482
J Am Med Inform Assoc. 2016 Apr;23(e1):e108-12
pubmed: 26554427
PLoS One. 2016 Mar 16;11(3):e0150514
pubmed: 26981866
Ann Allergy Asthma Immunol. 2016 Jul;117(1):67-71
pubmed: 27211057
J Allergy Clin Immunol. 2015 Sep;136(3):685-691.e3
pubmed: 25930196